✦ LIBER ✦

Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia

✍ Scribed by van der Pol, M A; Pater, J M; Feller, N; Westra, A H; van Stijn, A; Ossenkoppele, G J; Broxterman, H J; Schuurhuis, G J

Book ID: 110055005
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 227 KB
Volume: 15
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402245

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Minimal residual disease in acute myeloi

Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis

✍ van der Pol, M A; Feller, N; Ossenkoppele, G J; Weijers, G W D; Westra, A H; van 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 108 KB

Immunocytochemical detection of the mult

Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status

✍ Filipits, M; Suchomel, R W; Lechner, K; Pirker, R 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 205 KB

Activity and expression of the multidrug

Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia

✍ van der Kolk, D M; de Vries, E G E; Noordhoek, L; van den Berg, E; van der Pol, 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 197 KB

Theoretical and practical considerations

Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia

✍ Broxterman, H J; Lankelma, J; Pinedo, H M; Eekman, C A; Währer, D C R; Ossenkopp 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 261 KB

Determination of P-glycoprotein, MDR-rel

Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia

✍ Lorena L. de Figueiredo-Pontes; Maria-Carolina T. Pintão; Luciana C. O. Oliveira 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB

Expression patterns of WT1 and PRAME in

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease

✍ YaZhen Qin; HongHu Zhu; Bin Jiang; JinLan Li; XiJing Lu; LingDi Li; GuoRui Ruan; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Both WT1 and PRAME are highly expressed in acute myeloid leukemia (AML) patients. To assess the efficacy of their simultaneous detection for the purpose of monitoring minimal residual disease (MRD), we used real-time quantitative RT-PCR to quantify both WT1 and PRAME transcript levels in the bone ma